The R21/Matrix-M vaccine price will decrease to $2.99 per dose within a year, saving up to $90 million and enabling nations to secure over 30 million extra doses in the next five years. “This is a prime example of our Vaccine Alliance’s work,” said An Vermeersch, head of Gavi’s vaccine programs. “We leverage innovative financing and partnerships to provide affordable vaccines for children against Africa’s deadly diseases.”
Malaria remains a leading infectious disease, causing around 597,000 deaths in 2023, primarily in young African children. “This devastating toll demands action,” said Leila Pakkala, director of UNICEF’s Supply Division. “Despite declining international aid, UNICEF is committed to working with partners to supply vaccines at the best price to protect children.” The pricing agreement was made possible by an advance payment through the International Finance Facility for Immunization (IFFIm), converting long-term pledges into immediate funds, allowing Gavi to act swiftly in developing markets.
“IFFIm transforms ambition into action,” said Ken Lay, Chairman of the IFFIm Board. “Financial innovation can save lives.” Over 40 million malaria vaccine doses have been distributed through Gavi-supported programs, with 24 African nations incorporating them into routine immunization. Demand is high: 14 countries introduced the vaccine last year, with seven more set for 2025. The lower price aids Gavi’s goal to fully vaccinate 50 million more children against malaria by the decade’s end.
Both WHO-recommended malaria vaccines, R21/Matrix-M and RTS,S, have reduced malaria cases by over half in the first year post-vaccination, with further protection from booster doses. For families and health systems already burdened by the disease, expanded rollout could be transformative. “It’s about giving every child a fair chance to be protected,” Lay said. “It’s about saving lives now.”
Leave a Reply